GSK (NYSE:GSK) Updates FY 2025 Earnings Guidance

GSK (NYSE:GSK) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.090-2.130 for the period, compared to the consensus earnings per share estimate of 4.520. The company issued revenue guidance of $40.1 billion-$40.9 billion, compared to the consensus revenue estimate of $34.3 billion.

Analyst Upgrades and Downgrades

GSK has been the subject of several research reports. StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Six research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

GSK stock opened at $36.39 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK has a 12 month low of $31.72 and a 12 month high of $45.92. The stock has a market cap of $75.41 billion, a PE ratio of 23.64, a P/E/G ratio of 1.38 and a beta of 0.64. The company has a 50-day moving average price of $34.21 and a 200 day moving average price of $37.60.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 50.62% and a net margin of 7.97%. Equities research analysts anticipate that GSK will post 3.92 earnings per share for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.32%. GSK’s dividend payout ratio (DPR) is presently 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.